Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. A Pooled Analysis of 5 Randomized Control Trials

Camille G. Frazier, Karen P. Alexander, L. Kristin Newby, Susan Anderson, Erik Iverson, Milton Packer, Jay N Cohn, Sidney Goldstein, Pamela S. Douglas

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Objectives: This study sought to explore the gender-related differences in etiology and outcomes in chronic heart failure (HF) patients from 5 randomized trials. Background: Each year, 550,000 new cases of HF are identified; however, there remain limited data on gender-related differences in etiology and outcomes among patients with HF with systolic dysfunction. Methods: We analyzed data from 8,791 men and 2,851 women randomized in 5 clinical trials (PRAISE [Prospective Randomized Amlodipine Survival Evaluation], PRAISE-2, MERIT-HF [Metoprolol Extended Release Randomized Intervention Trial in Heart Failure], VEST [Vesnarinone Trial], and PROMISE [Prospective Randomized Milrinone Survival Evaluation]) to explore gender-related differences in etiology (ischemic vs. nonischemic) and outcomes (all-cause mortality and death or all-cause hospitalization). Hazard ratios (HR), 95% confidence intervals (CIs), and Kaplan-Meier survival curves were generated by gender and etiology. Results: A total of 18% of ischemic and 31% of nonischemic patients were women. Irrespective of etiology, women were older, more ethnically diverse, and had higher systolic blood pressures, more diabetes, and severe HF symptoms, but less often smoked or had prior myocardial infarctions than men. Mean ejection fractions were similar between women (23.6%) and men (23.2%). The 1-year Kaplan-Meier survival estimates varied by gender and etiology (female nonischemics, HR 0.88 [95% CI 0.85 to 0.89]; female ischemics, HR 0.83 [95% CI 0.81 to 0.85]; male nonischemics, HR 0.84 [95% CI 0.83 to 0.85]; male ischemics, HR 0.79 [95% CI 0.78 to 0.81]). After adjustment, female gender (HR 0.77 [95% CI 0.69 to 0.85]) and nonischemic etiology (HR 0.80 [95% CI 0.72 to 0.89]) were associated with longer survival time. Time to death or hospitalization was longer among nonischemics (HR 0.83 [95% CI 0.78 to 0.89], p < 0.0001); however, female gender was not significantly associated with the composite outcome (HR 1.01 [95% CI 0.95 to 1.08]). Conclusions: Our data clarify that outcomes differ by both gender and etiology among patients with HF with systolic dysfunction. Understanding these differences may lead to better management of HF patients and improved overall prognosis.

Original languageEnglish (US)
Pages (from-to)1450-1458
Number of pages9
JournalJournal of the American College of Cardiology
Volume49
Issue number13
DOIs
StatePublished - Apr 3 2007

Fingerprint

Systolic Heart Failure
Confidence Intervals
Heart Failure
Survival
Kaplan-Meier Estimate
Hospitalization
Milrinone
Amlodipine
Metoprolol
Cause of Death
Randomized Controlled Trials
Myocardial Infarction
Blood Pressure
Hypertension

Cite this

Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. A Pooled Analysis of 5 Randomized Control Trials. / Frazier, Camille G.; Alexander, Karen P.; Newby, L. Kristin; Anderson, Susan; Iverson, Erik; Packer, Milton; Cohn, Jay N; Goldstein, Sidney; Douglas, Pamela S.

In: Journal of the American College of Cardiology, Vol. 49, No. 13, 03.04.2007, p. 1450-1458.

Research output: Contribution to journalArticle

Frazier, Camille G. ; Alexander, Karen P. ; Newby, L. Kristin ; Anderson, Susan ; Iverson, Erik ; Packer, Milton ; Cohn, Jay N ; Goldstein, Sidney ; Douglas, Pamela S. / Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. A Pooled Analysis of 5 Randomized Control Trials. In: Journal of the American College of Cardiology. 2007 ; Vol. 49, No. 13. pp. 1450-1458.
@article{fd5537d2931a448eaf44ad85475a1d25,
title = "Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. A Pooled Analysis of 5 Randomized Control Trials",
abstract = "Objectives: This study sought to explore the gender-related differences in etiology and outcomes in chronic heart failure (HF) patients from 5 randomized trials. Background: Each year, 550,000 new cases of HF are identified; however, there remain limited data on gender-related differences in etiology and outcomes among patients with HF with systolic dysfunction. Methods: We analyzed data from 8,791 men and 2,851 women randomized in 5 clinical trials (PRAISE [Prospective Randomized Amlodipine Survival Evaluation], PRAISE-2, MERIT-HF [Metoprolol Extended Release Randomized Intervention Trial in Heart Failure], VEST [Vesnarinone Trial], and PROMISE [Prospective Randomized Milrinone Survival Evaluation]) to explore gender-related differences in etiology (ischemic vs. nonischemic) and outcomes (all-cause mortality and death or all-cause hospitalization). Hazard ratios (HR), 95{\%} confidence intervals (CIs), and Kaplan-Meier survival curves were generated by gender and etiology. Results: A total of 18{\%} of ischemic and 31{\%} of nonischemic patients were women. Irrespective of etiology, women were older, more ethnically diverse, and had higher systolic blood pressures, more diabetes, and severe HF symptoms, but less often smoked or had prior myocardial infarctions than men. Mean ejection fractions were similar between women (23.6{\%}) and men (23.2{\%}). The 1-year Kaplan-Meier survival estimates varied by gender and etiology (female nonischemics, HR 0.88 [95{\%} CI 0.85 to 0.89]; female ischemics, HR 0.83 [95{\%} CI 0.81 to 0.85]; male nonischemics, HR 0.84 [95{\%} CI 0.83 to 0.85]; male ischemics, HR 0.79 [95{\%} CI 0.78 to 0.81]). After adjustment, female gender (HR 0.77 [95{\%} CI 0.69 to 0.85]) and nonischemic etiology (HR 0.80 [95{\%} CI 0.72 to 0.89]) were associated with longer survival time. Time to death or hospitalization was longer among nonischemics (HR 0.83 [95{\%} CI 0.78 to 0.89], p < 0.0001); however, female gender was not significantly associated with the composite outcome (HR 1.01 [95{\%} CI 0.95 to 1.08]). Conclusions: Our data clarify that outcomes differ by both gender and etiology among patients with HF with systolic dysfunction. Understanding these differences may lead to better management of HF patients and improved overall prognosis.",
author = "Frazier, {Camille G.} and Alexander, {Karen P.} and Newby, {L. Kristin} and Susan Anderson and Erik Iverson and Milton Packer and Cohn, {Jay N} and Sidney Goldstein and Douglas, {Pamela S.}",
year = "2007",
month = "4",
day = "3",
doi = "10.1016/j.jacc.2006.11.041",
language = "English (US)",
volume = "49",
pages = "1450--1458",
journal = "Journal of the American College of Cardiology.",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "13",

}

TY - JOUR

T1 - Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. A Pooled Analysis of 5 Randomized Control Trials

AU - Frazier, Camille G.

AU - Alexander, Karen P.

AU - Newby, L. Kristin

AU - Anderson, Susan

AU - Iverson, Erik

AU - Packer, Milton

AU - Cohn, Jay N

AU - Goldstein, Sidney

AU - Douglas, Pamela S.

PY - 2007/4/3

Y1 - 2007/4/3

N2 - Objectives: This study sought to explore the gender-related differences in etiology and outcomes in chronic heart failure (HF) patients from 5 randomized trials. Background: Each year, 550,000 new cases of HF are identified; however, there remain limited data on gender-related differences in etiology and outcomes among patients with HF with systolic dysfunction. Methods: We analyzed data from 8,791 men and 2,851 women randomized in 5 clinical trials (PRAISE [Prospective Randomized Amlodipine Survival Evaluation], PRAISE-2, MERIT-HF [Metoprolol Extended Release Randomized Intervention Trial in Heart Failure], VEST [Vesnarinone Trial], and PROMISE [Prospective Randomized Milrinone Survival Evaluation]) to explore gender-related differences in etiology (ischemic vs. nonischemic) and outcomes (all-cause mortality and death or all-cause hospitalization). Hazard ratios (HR), 95% confidence intervals (CIs), and Kaplan-Meier survival curves were generated by gender and etiology. Results: A total of 18% of ischemic and 31% of nonischemic patients were women. Irrespective of etiology, women were older, more ethnically diverse, and had higher systolic blood pressures, more diabetes, and severe HF symptoms, but less often smoked or had prior myocardial infarctions than men. Mean ejection fractions were similar between women (23.6%) and men (23.2%). The 1-year Kaplan-Meier survival estimates varied by gender and etiology (female nonischemics, HR 0.88 [95% CI 0.85 to 0.89]; female ischemics, HR 0.83 [95% CI 0.81 to 0.85]; male nonischemics, HR 0.84 [95% CI 0.83 to 0.85]; male ischemics, HR 0.79 [95% CI 0.78 to 0.81]). After adjustment, female gender (HR 0.77 [95% CI 0.69 to 0.85]) and nonischemic etiology (HR 0.80 [95% CI 0.72 to 0.89]) were associated with longer survival time. Time to death or hospitalization was longer among nonischemics (HR 0.83 [95% CI 0.78 to 0.89], p < 0.0001); however, female gender was not significantly associated with the composite outcome (HR 1.01 [95% CI 0.95 to 1.08]). Conclusions: Our data clarify that outcomes differ by both gender and etiology among patients with HF with systolic dysfunction. Understanding these differences may lead to better management of HF patients and improved overall prognosis.

AB - Objectives: This study sought to explore the gender-related differences in etiology and outcomes in chronic heart failure (HF) patients from 5 randomized trials. Background: Each year, 550,000 new cases of HF are identified; however, there remain limited data on gender-related differences in etiology and outcomes among patients with HF with systolic dysfunction. Methods: We analyzed data from 8,791 men and 2,851 women randomized in 5 clinical trials (PRAISE [Prospective Randomized Amlodipine Survival Evaluation], PRAISE-2, MERIT-HF [Metoprolol Extended Release Randomized Intervention Trial in Heart Failure], VEST [Vesnarinone Trial], and PROMISE [Prospective Randomized Milrinone Survival Evaluation]) to explore gender-related differences in etiology (ischemic vs. nonischemic) and outcomes (all-cause mortality and death or all-cause hospitalization). Hazard ratios (HR), 95% confidence intervals (CIs), and Kaplan-Meier survival curves were generated by gender and etiology. Results: A total of 18% of ischemic and 31% of nonischemic patients were women. Irrespective of etiology, women were older, more ethnically diverse, and had higher systolic blood pressures, more diabetes, and severe HF symptoms, but less often smoked or had prior myocardial infarctions than men. Mean ejection fractions were similar between women (23.6%) and men (23.2%). The 1-year Kaplan-Meier survival estimates varied by gender and etiology (female nonischemics, HR 0.88 [95% CI 0.85 to 0.89]; female ischemics, HR 0.83 [95% CI 0.81 to 0.85]; male nonischemics, HR 0.84 [95% CI 0.83 to 0.85]; male ischemics, HR 0.79 [95% CI 0.78 to 0.81]). After adjustment, female gender (HR 0.77 [95% CI 0.69 to 0.85]) and nonischemic etiology (HR 0.80 [95% CI 0.72 to 0.89]) were associated with longer survival time. Time to death or hospitalization was longer among nonischemics (HR 0.83 [95% CI 0.78 to 0.89], p < 0.0001); however, female gender was not significantly associated with the composite outcome (HR 1.01 [95% CI 0.95 to 1.08]). Conclusions: Our data clarify that outcomes differ by both gender and etiology among patients with HF with systolic dysfunction. Understanding these differences may lead to better management of HF patients and improved overall prognosis.

UR - http://www.scopus.com/inward/record.url?scp=33947576171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947576171&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2006.11.041

DO - 10.1016/j.jacc.2006.11.041

M3 - Article

VL - 49

SP - 1450

EP - 1458

JO - Journal of the American College of Cardiology.

JF - Journal of the American College of Cardiology.

SN - 0735-1097

IS - 13

ER -